Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q92966
UPID:
SNPC3_HUMAN
Alternative names:
Proximal sequence element-binding transcription factor subunit beta; Small nuclear RNA-activating complex polypeptide 3; snRNA-activating protein complex 50 kDa subunit
Alternative UPACC:
Q92966; D3DRI8; Q2VPI6; Q5T285
Background:
The snRNA-activating protein complex subunit 3, also known as Proximal sequence element-binding transcription factor subunit beta, plays a crucial role in the transcription of RNA polymerase II and III small-nuclear RNA genes. It binds to the proximal sequence element (PSE), facilitating the recruitment of TBP and BRF2 to the U6 snRNA TATA box.
Therapeutic significance:
Understanding the role of snRNA-activating protein complex subunit 3 could open doors to potential therapeutic strategies.